New styrene-b-isobutylene-b-styrene (SIBS) glaucoma drainage implant

Marcia Orozco, Ana C. Acosta, Edgar M. Espana, Leonard Pinchuk, Bruce Weber, Stewart Davis, Esdras Arrieta Quintero, Sander Dubovy, Francisco Fantes, Mohamed Aly, Yonghua Zhou, Jean-Marie A Parel

Research output: Chapter in Book/Report/Conference proceedingConference contribution

2 Citations (Scopus)

Abstract

Purpose: To design and test the Miami-InnFocus Drainage Implant (MiDi) as a glaucoma shunt that is biocompatible, flexible, and significantly smaller than existing commercial implants in order to prevent postoperative hypotony, inflammation, scarring, erosion, and extrusion. Methods: A new biomaterial composed of styrene-b-isobutylene-b-styrene (SIBS) was used in a novel design for a glaucoma drainage implant. The implant consists of a tube 11mm long with an inner diameter of 70, 100, and 150 μm and outer diameter of 250 μm with a 1mm 2 tab located 4.5mm from the proximal tip to prevent migration. The device was implanted in 15 New Zealand White rabbits for biocompatibility and efficacy testing. A similarly designed implant made of polydimethylsiloxane was implanted in 6 other animals as a pseudo-control. Typical GDI implantation technique was modified for this device. The proximal end of the new SIBS implant was inserted 2mm into the anterior chamber and the distal end placed in a subconjunctival space created by the surgeon. Biocompatibility of the device was studied by slit-lamp follow-up and intraocular pressure (IOP) measurements recorded periodically. Results: Biocompatibility of the MiDi was excellent. A low and diffuse bleb was observed with these devices. All SIBS tubes were patent 9 months after insertion. Immunostaining demonstrated non-continuous deposition of collagen with virtually no encapsulation. No macrophages or myofibroblast were visible around the SIBS polymer which was found more bioinert than the control PDMS. Conclusion: This newly designed glaucoma implant is clinically biocompatible in the rabbit model and maintained 100% patency at 9 months.

Original languageEnglish
Title of host publicationProgress in Biomedical Optics and Imaging - Proceedings of SPIE
Volume6138
DOIs
StatePublished - Jun 30 2006
EventOphthalmic Technologies XVI - San Jose, CA, United States
Duration: Jan 21 2006Jan 24 2006

Other

OtherOphthalmic Technologies XVI
CountryUnited States
CitySan Jose, CA
Period1/21/061/24/06

Fingerprint

Drainage
Styrene
Biocompatibility
Macrophages
Polydimethylsiloxane
Pressure measurement
Electric lamps
Encapsulation
Collagen
Biomaterials
Extrusion
Erosion
Animals
Testing
Polymers

Keywords

  • Aqueous
  • Biocompatibility
  • Intraocular pressure
  • Wound healing

ASJC Scopus subject areas

  • Engineering(all)

Cite this

Orozco, M., Acosta, A. C., Espana, E. M., Pinchuk, L., Weber, B., Davis, S., ... Parel, J-M. A. (2006). New styrene-b-isobutylene-b-styrene (SIBS) glaucoma drainage implant. In Progress in Biomedical Optics and Imaging - Proceedings of SPIE (Vol. 6138). [61380U] https://doi.org/10.1117/12.652297

New styrene-b-isobutylene-b-styrene (SIBS) glaucoma drainage implant. / Orozco, Marcia; Acosta, Ana C.; Espana, Edgar M.; Pinchuk, Leonard; Weber, Bruce; Davis, Stewart; Arrieta Quintero, Esdras; Dubovy, Sander; Fantes, Francisco; Aly, Mohamed; Zhou, Yonghua; Parel, Jean-Marie A.

Progress in Biomedical Optics and Imaging - Proceedings of SPIE. Vol. 6138 2006. 61380U.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Orozco, M, Acosta, AC, Espana, EM, Pinchuk, L, Weber, B, Davis, S, Arrieta Quintero, E, Dubovy, S, Fantes, F, Aly, M, Zhou, Y & Parel, J-MA 2006, New styrene-b-isobutylene-b-styrene (SIBS) glaucoma drainage implant. in Progress in Biomedical Optics and Imaging - Proceedings of SPIE. vol. 6138, 61380U, Ophthalmic Technologies XVI, San Jose, CA, United States, 1/21/06. https://doi.org/10.1117/12.652297
Orozco M, Acosta AC, Espana EM, Pinchuk L, Weber B, Davis S et al. New styrene-b-isobutylene-b-styrene (SIBS) glaucoma drainage implant. In Progress in Biomedical Optics and Imaging - Proceedings of SPIE. Vol. 6138. 2006. 61380U https://doi.org/10.1117/12.652297
Orozco, Marcia ; Acosta, Ana C. ; Espana, Edgar M. ; Pinchuk, Leonard ; Weber, Bruce ; Davis, Stewart ; Arrieta Quintero, Esdras ; Dubovy, Sander ; Fantes, Francisco ; Aly, Mohamed ; Zhou, Yonghua ; Parel, Jean-Marie A. / New styrene-b-isobutylene-b-styrene (SIBS) glaucoma drainage implant. Progress in Biomedical Optics and Imaging - Proceedings of SPIE. Vol. 6138 2006.
@inproceedings{1b5385a5ac3746ad9451ca66deb08ff5,
title = "New styrene-b-isobutylene-b-styrene (SIBS) glaucoma drainage implant",
abstract = "Purpose: To design and test the Miami-InnFocus Drainage Implant (MiDi) as a glaucoma shunt that is biocompatible, flexible, and significantly smaller than existing commercial implants in order to prevent postoperative hypotony, inflammation, scarring, erosion, and extrusion. Methods: A new biomaterial composed of styrene-b-isobutylene-b-styrene (SIBS) was used in a novel design for a glaucoma drainage implant. The implant consists of a tube 11mm long with an inner diameter of 70, 100, and 150 μm and outer diameter of 250 μm with a 1mm 2 tab located 4.5mm from the proximal tip to prevent migration. The device was implanted in 15 New Zealand White rabbits for biocompatibility and efficacy testing. A similarly designed implant made of polydimethylsiloxane was implanted in 6 other animals as a pseudo-control. Typical GDI implantation technique was modified for this device. The proximal end of the new SIBS implant was inserted 2mm into the anterior chamber and the distal end placed in a subconjunctival space created by the surgeon. Biocompatibility of the device was studied by slit-lamp follow-up and intraocular pressure (IOP) measurements recorded periodically. Results: Biocompatibility of the MiDi was excellent. A low and diffuse bleb was observed with these devices. All SIBS tubes were patent 9 months after insertion. Immunostaining demonstrated non-continuous deposition of collagen with virtually no encapsulation. No macrophages or myofibroblast were visible around the SIBS polymer which was found more bioinert than the control PDMS. Conclusion: This newly designed glaucoma implant is clinically biocompatible in the rabbit model and maintained 100{\%} patency at 9 months.",
keywords = "Aqueous, Biocompatibility, Intraocular pressure, Wound healing",
author = "Marcia Orozco and Acosta, {Ana C.} and Espana, {Edgar M.} and Leonard Pinchuk and Bruce Weber and Stewart Davis and {Arrieta Quintero}, Esdras and Sander Dubovy and Francisco Fantes and Mohamed Aly and Yonghua Zhou and Parel, {Jean-Marie A}",
year = "2006",
month = "6",
day = "30",
doi = "10.1117/12.652297",
language = "English",
isbn = "0819461814",
volume = "6138",
booktitle = "Progress in Biomedical Optics and Imaging - Proceedings of SPIE",

}

TY - GEN

T1 - New styrene-b-isobutylene-b-styrene (SIBS) glaucoma drainage implant

AU - Orozco, Marcia

AU - Acosta, Ana C.

AU - Espana, Edgar M.

AU - Pinchuk, Leonard

AU - Weber, Bruce

AU - Davis, Stewart

AU - Arrieta Quintero, Esdras

AU - Dubovy, Sander

AU - Fantes, Francisco

AU - Aly, Mohamed

AU - Zhou, Yonghua

AU - Parel, Jean-Marie A

PY - 2006/6/30

Y1 - 2006/6/30

N2 - Purpose: To design and test the Miami-InnFocus Drainage Implant (MiDi) as a glaucoma shunt that is biocompatible, flexible, and significantly smaller than existing commercial implants in order to prevent postoperative hypotony, inflammation, scarring, erosion, and extrusion. Methods: A new biomaterial composed of styrene-b-isobutylene-b-styrene (SIBS) was used in a novel design for a glaucoma drainage implant. The implant consists of a tube 11mm long with an inner diameter of 70, 100, and 150 μm and outer diameter of 250 μm with a 1mm 2 tab located 4.5mm from the proximal tip to prevent migration. The device was implanted in 15 New Zealand White rabbits for biocompatibility and efficacy testing. A similarly designed implant made of polydimethylsiloxane was implanted in 6 other animals as a pseudo-control. Typical GDI implantation technique was modified for this device. The proximal end of the new SIBS implant was inserted 2mm into the anterior chamber and the distal end placed in a subconjunctival space created by the surgeon. Biocompatibility of the device was studied by slit-lamp follow-up and intraocular pressure (IOP) measurements recorded periodically. Results: Biocompatibility of the MiDi was excellent. A low and diffuse bleb was observed with these devices. All SIBS tubes were patent 9 months after insertion. Immunostaining demonstrated non-continuous deposition of collagen with virtually no encapsulation. No macrophages or myofibroblast were visible around the SIBS polymer which was found more bioinert than the control PDMS. Conclusion: This newly designed glaucoma implant is clinically biocompatible in the rabbit model and maintained 100% patency at 9 months.

AB - Purpose: To design and test the Miami-InnFocus Drainage Implant (MiDi) as a glaucoma shunt that is biocompatible, flexible, and significantly smaller than existing commercial implants in order to prevent postoperative hypotony, inflammation, scarring, erosion, and extrusion. Methods: A new biomaterial composed of styrene-b-isobutylene-b-styrene (SIBS) was used in a novel design for a glaucoma drainage implant. The implant consists of a tube 11mm long with an inner diameter of 70, 100, and 150 μm and outer diameter of 250 μm with a 1mm 2 tab located 4.5mm from the proximal tip to prevent migration. The device was implanted in 15 New Zealand White rabbits for biocompatibility and efficacy testing. A similarly designed implant made of polydimethylsiloxane was implanted in 6 other animals as a pseudo-control. Typical GDI implantation technique was modified for this device. The proximal end of the new SIBS implant was inserted 2mm into the anterior chamber and the distal end placed in a subconjunctival space created by the surgeon. Biocompatibility of the device was studied by slit-lamp follow-up and intraocular pressure (IOP) measurements recorded periodically. Results: Biocompatibility of the MiDi was excellent. A low and diffuse bleb was observed with these devices. All SIBS tubes were patent 9 months after insertion. Immunostaining demonstrated non-continuous deposition of collagen with virtually no encapsulation. No macrophages or myofibroblast were visible around the SIBS polymer which was found more bioinert than the control PDMS. Conclusion: This newly designed glaucoma implant is clinically biocompatible in the rabbit model and maintained 100% patency at 9 months.

KW - Aqueous

KW - Biocompatibility

KW - Intraocular pressure

KW - Wound healing

UR - http://www.scopus.com/inward/record.url?scp=33745351471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745351471&partnerID=8YFLogxK

U2 - 10.1117/12.652297

DO - 10.1117/12.652297

M3 - Conference contribution

SN - 0819461814

SN - 9780819461810

VL - 6138

BT - Progress in Biomedical Optics and Imaging - Proceedings of SPIE

ER -